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Dihydrofolate reductase (DHFR) is a critical enzyme in the folate metabolism pathway and also plays a role in regulating nitric
oxide (NO) signaling in endothelial cells. Although both coding and noncoding mutations with phenotypic effects have been
identified in the humanDHFR gene, no mouse model is currently available to study the consequences of perturbing DHFR in
vivo. In order to identify genes involved in definitive hematopoiesis, we performed a forward genetic screen and produced a
mouse line, here referred to as Orana, with a point mutation in theDhfr locus leading to a Thr136Ala substitution in the DHFR
protein. Homozygote Orana mice initiate definitive hematopoiesis, but expansion of progenitors in the fetal liver is compro-
mised, and the animals die between embryonic day 13.5 (E13.5) and E14.5. Heterozygote Orana mice survive to adulthood but
have tissue-specific alterations in folate abundance and distribution, perturbed stress erythropoiesis, and impaired endotheli-
um-dependent relaxation of the aorta consistent with the role of DHFR in regulating NO signaling. Orana mice provide insight
into the dual roles of DHFR and are a useful model for investigating the role of environmental and dietary factors in the context
of vascular defects caused by altered NO signaling.
The primary role of dihydrofolate reductase (DHFR) (5,6,7,8-tetrahydrofolate:NADPoxidoreductase; EC 1.5.1.3) is to cat-
alyze the reduction of dietary folate to 7,8-dihydrofolate (DHF)
and the subsequent reduction of DHF to 5,6,7,8-tetrahydrofolate
(THF). THF, via the actions of a host of other enzymes, is a pre-
cursor for 5-methyl THF, which is critical for maintaining DNA
methylation, and 5-10-methylene THF, which is required for syn-
thesis of both thymidylate and purine and is thus critical for DNA
replication and repair (1). In humans, DHFR-reduced dietary fo-
late is the only source of THF. As such, DHFR is important for
ensuring normal DNA synthesis and methylation (1). DHFR also
plays a secondary role in nitric oxide (NO) signaling in endothelial
cells, where it catalyzes the reduction of dihydrobiopterin (BH2)
to tetrahydrobiopterin (BH4), an essential cofactor for endothe-
lial NO synthase (eNOS) (2–4). Reduced intracellular levels of
BH4 and/or alteration of the BH4/BH2 ratio in favor of the latter
leads to eNOS uncoupling, a process by which eNOS switches
from producing the vasoprotective NO to generating the super-
oxide anion radical (O2·
) (5), which promotes endothelial dys-
function (6).
Due to its essential role in DNA replication and repair, DHFR
is an important target of antineoplastic drugs, such as methotrex-
ate (MTX) (7), and thus, the biochemical properties of DHFR
have been studied in relation to normal folate metabolism and in
the development of antifolate drugs. Genetic studies have identi-
fied both noncoding and coding mutations in the DHFR locus.
Noncoding mutations have been described in the promoter, the
intronic regions, and the 3= untranslated region (UTR) (8). The
precise roles of these variations are unclear. The best-studied vari-
ation is a 19-bp deletion in intron 1 that has been associated with
neural tube defects in the offspring of female carriers; however,
multiple studies have produced conflicting results regarding
whether this deletion increases or decreases the risk of neural tube
defects (9, 10). Other variations have been less well studied but are
linked to both cancer susceptibility and resistance to MTX (11–
14). Two protein-coding mutations in DHFR have also been de-
scribed. Patients homozygous for the Leu80Phe mutation (15)
had megaloblastic anemia and/or pancytopenia and cerebral fo-
late and BH4 deficiencies, while patients homozygous for the
Asp153Val mutation (16) had megaloblastic anemia and mild
learning disabilities.
However, despite the critical roles of DHFR and folate metab-
olism in human health and disease, no animal models are cur-
rently available to study the effect of null or loss-of-function
DHFR alleles on normal development and tissue homeostasis.
Cell line models are also limited in their capacity to yield insights
into tissue- and locus-specific aberrations in DNA methylation
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and cancer susceptibility in the presence of persistent abnormali-
ties in tissue folate metabolism.
Ethylnitrosourea (ENU) mutagenesis is a powerful tool for
generating point mutations in mice that can then be screened for
phenotypic effects (17). Such screens have the advantage of poten-
tially generating loss- or gain-of-function alleles, as opposed to
knockout mice, which are generally limited to removing a func-
tional allele. In this study, we describe a mouse generated through
an ENU mutagenesis screen followed by extensive backcrossing,
with a single point mutation in the Dhfr locus leading to a
Thr136Ala substitution in the DHFR protein. Homozygote ani-
mals die of blood defects between embryonic day 13.5 (E13.5) and
E14.5, while heterozygote adults survive with a relatively intact
blood compartment but show tissue-specific defects in distribu-
tion of folate species and impaired stress-induced hematopoiesis
and blood vessel relaxation.
MATERIALS AND METHODS
Generation of mice, phenotyping, and mapping. The Orana (Ora)
mouse line was generated by ENU mutagenesis followed by a screen for
recessive hematopoietic phenotypes, as described previously (18). Briefly,
fetal livers (FLs) from E14.5 embryos were screened by flow cytometry in
order to enumerate six distinct hematopoietic stem cell (HSC) and pro-
genitor subsets (long-term hematopoietic stem cells [LT-HSCs], multi-
potent progenitors [MPPs], common lymphoid progenitors [CLPs],
common myeloid progenitors [CMPs], granulocyte/macrophage progen-
itors [GMPs], and megakaryocyte/erythrocyte progenitors [MEPs]), and
fetal blood (FB) from E14.5 embryos was screened by flow cytometry to
enumerate yolk sac-derived primitive red blood cells (RBCs), FL-derived
definitive RBCs, and platelets. For linkage analysis, genomic DNA from 7
affected and 12 unaffected F2 C57BL/6J  C57BL/10SnJ mice was
screened with approximately 80 strain-specific single nucleotide poly-
morphism (SNP) markers spaced at 20- to 30-Mb positions on each
chromosome using the Amplifluor SNP genotyping system (Chemi-
con, Millipore). The Orana causal mutation was mapped to a region on
chromosome 13 between bases 66366699 and 101979187 (mm9),
which contained 307 genes. Of these, three candidate genes (Mtrr
[ENSMUSG00000034617], Dhfr [ENSMUSG00000021707], and Tert
[ENSMUSG00000021611]) with known or suspected roles in blood de-
velopment were selected for sequence analysis. Sequencing of the candi-
date genes was performed to locate the causal ENU base substitution, and
DNA was prepared from an individual affected mouse. Primers were de-
signed for candidate genes to amplify all exons by15 bp to cover splice
junctions. The amplicons were then Sanger sequenced on an Applied
Biosystems 3730xl capillary sequencer. This automated platform uses Big-
Dye Terminator (BDT) chemistry version 3.1 (Applied Biosystems). The
raw trace files were analyzed using Lasergene software (DNAStar)
against the C57BL/6 mouse reference genome (NCBI). Using this ap-
proach, a single base substitution (A to G) of base pair 885 in exon 5
(ENSMUSE00000120178) was detected inDhfr. This mutation results in
an ACA (Thr)-to-GCA (Ala) change of amino acid 136. All animal exper-
iments were performed with approval from the University of New South
Wales Animal Ethics committee.
Primers and antibodies. The PCR primers used were as follows: for
genotyping, Orana-1 (5=-GAAGGTCGGAGTCAACGGATTCTTTCAAA
TTCCTGCATGATCCTTGT-3=), Orana-2 (5=-GAAGGTGACCAAGTT
CATGCTCAAATTCCTGCATGATCCTTGC-3=), and Orana-R (5=-GAG
GAGAGTGATACCTTGTGTT-3=); for expression, mDHFR F (5=-GTAG
AGAACTCAAAGAACCACCAC-3=), mDHFR R (5=-CAGAACTGCCTC
CGACTATCC-3=), mB2M F (5=-GAGACTGATACATACGCCTGCAG
A-3=), and mB2M R (5=-TCACATGTCTCGATCCCAGTAGA-3=); for
cloning and mutagenesis, mut hDHFR F (5=-CAGGCCATCTTAAACTA
TTTGTGGCAAGG-3=), mut hDHFR R (5=-CACTTTCAAAGTCTTGCA
TGATCCTTGCCAC-3=), hDHFR F (5=-TCCCGGGTCATGGTTGGTT
CGCTAAACTGC-3=), hDHFR F2 (5=-TCCCGGGTATGGTTGGTTCGC
TAAACTGC-3=), and hDHFR R (5=-GTCGACCTCGAGTATTAATCAT
TCTTCTCATATAC-3=); for sequencing, hDHFR seq 1 (5=-CGCTGTGT
CCCAGAACATGGGC-3=), hDHFR seq 2 (5=-GCCTTTCTCCTCCTGG
ACATC), mDHFR seq 1 (5=-CTGCCTTTCAGCACAGGTTG-3=), and
mDHFR seq 2 (5=-TTACTTGCTTCCCCTTCTTTCTG-3=); for pyrose-
quencing, mKcnq1ot1 F (5=-GYGYGGGTTTTTTTTTTGAGTTAGT),
mKcnq1ot1 R 5= biotinylated (5=-CRATATCCTAAACCACTCACCTTA-
3=), and mKcnq1ot1 sequencing (5=-GTTAGAAGTAGAGGTGAT-3=).
The antibodies used were as follows: from Abcam, anti-DHFR
(ab133546); from BD, streptavidin-phycoerythrin-Texas red (551487), anti-
mouse CD117–allophycocyanin (APC) H7 (560250), anti-mouse Ly-
6A/E V500 (561229), anti-mouse CD34 –fluorescein isothiocyanate
(FITC) (553733), anti-mouse CD135–APC (560718), anti-mouse CD127–
phycoerythrin (PE) (552543), anti-mouse Ter119 –PE (553673), and
7-aminoactinomycin D (7-AAD) (559925); from BioLegend, anti-
mouse CD48 BV421 (103427) and anti-mouse CD150 (SLAM)–PE–
Cy5 (115911); and from eBiosciences, anti-mouse CD16/32–PE-Cy7
(25-0161-81), anti-mouse CD3e– biotin (13-0031), anti-mouse CD4 –
biotin (13-0041), anti-mouse CD5– biotin (13-0051), anti-mouse
CD8a– biotin (13-0081), anti-mouse CD45R/B220 – biotin (13-0452),
anti-mouse Ly-6G (Gr-1)– biotin (13-5931), anti-mouse CD11b
(Mac-1)– biotin (13-0112), anti-mouse Ter119 – biotin (13-5921),
anti-mouse CD44 –APC (17-0441-81), and anti-mouse CD177 (cKit)–
APC-eFluor780 (47-1171-80).
DNAandRNA isolation, cDNA synthesis, and qPCR.Genomic DNA
was prepared by proteinase K digestion of tissue and DNA. RNA was pre-
pared using the RNeasy minikit (Qiagen), and cDNA was synthesized using
standard protocols. Quantitative PCR (qPCR) was performed using SYBR
green ER (Life Technologies) and an MX3000P thermocycler (Agilent).
Protein isolation and Western blotting. Liver tissue for the DHFR
activity assay was homogenized in buffer (75 mM MnCl2, 2 mM dithio-
threitol [DTT], 1 mM EDTA plus protease inhibitors) and centrifuged at
17,000  g for 45 min, and the supernatant was stored at 80°C. The
protein concentration was estimated by Bradford assay (Bio-Rad).
Cells and tissue for Western blotting were solubilized in RIPA buffer
(50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% Triton X-100, 0.5% sodium
deoxycholate, 0.1% SDS, 1 mM EDTA) plus protease inhibitors, boiled in
sample buffer plus DTT, resolved in 4 to 12% Bis-Tris gels in MOPS
(4-morpholinepropanesulfonic acid) buffer (Novex), and transferred to
nitrocellulose membranes. The membranes were probed with antibodies
against DHFR or-actin, followed by secondary antibody, and developed
with Luminol reagent (Santa Cruz). Bands were detected using an Im-
ageQuant LAS4000 and quantified using ImageQuant software (GE).
DHFR expression vectors. The human DHFR cDNA was donated by
Tseng Ting Kao (National Cheng Kung University, Taiwan). Site-directed
mutagenesis was performed to introduce the Orana mutation. The DHFR
cDNA was PCR amplified and subcloned into either pGEX-6P-1 or
pcDNA3.
DHFR activity assay. Twenty microliters of liver lysate or recombi-
nant protein was added to 200 l of buffer (0.1 M potassium phosphate,
pH 7.4, 0.5 M KCl, 1 mM EDTA, 1 mM DTT, 20 mM sodium ascorbate)
and incubated for 9 min at 37°C, and then 150M NADPH was added for
an additional minute. Dihydrofolic acid (Sigma) was added to a final
concentration of 87M and incubated for 2 min. Reactions were stopped
by adding an equal volume of 0.5 M perchloric acid. Samples were centri-
fuged at 500 g for 2 min at 4°C and then filtered through a Chromadisk
4A microfilter and measured by high-performance liquid chromatogra-
phy (HPLC) and electrochemical detection (ECD) as described previously
(19).
Production of recombinant protein. pGEX-6P-1 DHFR-trans-
formed BL21 competent cells were grown to an optical density at 600 nm
(OD600) of 0.5 and induced with 0.15 mM isopropyl--D-thiogalactopy-
ranoside (IPTG) for 4 h at 30°C. EDTA (1 mM final concentration) was
added to stop the induction. The cells were pelleted and washed in phos-
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phate-buffered saline (PBS) and then lysed with buffer (50 mM Tris, pH
7.5, 150 mM NaCl, 5 mM EDTA, 0.5% NP-40, 1% Triton X-100, 10 mM
DTT plus protease inhibitors), sonicated, and centrifuged at 5,000 g for
15 min at 4°C. The supernatant was incubated with glutathione S-trans-
ferase (GST) beads (Roche) for 1 h and washed twice in PBS–1% Triton
X-100, and the purified protein was eluted with 100 mM Tris, pH 7.5, 20
mM NaCl, 10 mM glutathione.
Expression of DHFR in 293T cells. 293T cells were grown in Dulbec-
co’s modified Eagle’s medium (DMEM) containing 10% fetal bovine se-
rum (FBS). The cells were transfected using Lipofectamine 2000 (Life
Technologies) according to the manufacturer’s instructions; 24 h after
transfection, the cells were treated with 1M bortezomib (BTZ) (Janssen-
Cilag) for a further 24 h and then harvested in RIPA buffer supplemented
with protease inhibitors.
Measurement of folate species. The concentrations and distributions
of folate species were measured in 2 homozygous (Ora/Ora), 6 heterozy-
gous (/Ora), and 3 wild-type (WT) (/) E13.5 embryonic livers and
in the remaining embryonic tissue (whole embryos). Folate was also mea-
sured in six tissues (liver, brain, bone marrow [BM], aorta, colon, and
small intestine) in one/ and two/Ora adult mice. Where available,
100 mg of tissue was used for folate extraction; otherwise, 20 mg of tissue
was used, and the scale-down protocol for folate extraction was applied as
previously described (20, 21). The extraction of five folate species (THF,
folic acid, 5-methyl THF, 5-formyl THF, and 5,10-methenyl THF) from
tissues, purification by solid-phase extraction, and measurement using
liquid chromatography tandem mass spectrometry (LC–MS-MS) were
performed using a validated method, as previously described (21).
Measurement of global DNA methylation. 5-Methyl-2=-deoxycyt-
idine (5mdC) was determined as a percentage of 2=-deoxycytidine plus
5mdC in genomic DNA using stable-isotope dilution LC–MS-MS based
upon the method of Quinlivan and Gregory (22). In brief, this method
involves the in-house biosynthesis of [15N3]deoxycytidine ([
15N3]dC)
and [15N3]5mdC internal standards and one-step digestion of 1 g
genomic DNA spiked with U-15N-labeled internal standards into deoxy-
ribonucleosides (23). Genomic DNA was extracted from mouse whole-
embryo and adult tissues using phenol-chloroform-isoamyl alcohol and
quantified by measuring the UV absorbance at 260 nm (NanoDrop 1000;
NanoDrop Technologies Inc.). Purity was confirmed by a 260/280 ratio
of 1.8; 500 ng was used for the assay. The conditions for ultra-high-
performance liquid chromatography (UHPLC) and the triple-quadru-
pole mass spectrometer have been previously reported (20). Analyses were
performed using an ultra-high-performance liquid chromatography Ac-
cela Pump (Thermo Finnigan) and an HTC PAL (CTC Analytics) au-
tosampler coupled directly to a TSQ Quantum Access triple-quadrupole
relationship between folate distribution and DNA methylation 2 mass
spectrometer (Thermo Finnigan) in the positive-ion mode via an electro-
spray interface. LC was performed on an Acquity UHPLC HSS T3 column
(2.1 by 100 mm; 1.8 m). Twenty microliters of the sample was analyzed
using gradient elution with aqueous 0.1% formic acid (solvent A) and
acetonitrile (solvent B) at a flow rate of 0.4 ml/min over 7 min. The
acetonitrile gradient increased linearly from 0% at 0.7 min to 22.5% at 3.5
min, at which time it was ramped up to 100% by 3.85 min and held for
0.55 min before being returned to baseline at 4.55 min. The mass-to-
charge transitions of the analytes monitored were identical to those used
by Quinlivan and Gregory (22). Data were processed using the Quan-
browser function of the Xcalibur software package v2.0.7. In-house
method validation was performed as previously described (20). Four
quality control samples with known global DNA methylation levels (two
from human peripheral blood DNA and two from colorectal cancer cell
lines) and one blank sample were run with each batch of samples to check
for interbatch variation and to blank for unlabeled analytes in the internal
standard mixture (this was always	0.1%).
MeasurementofDNAmethylationbybisulfitepyrosequencing.The
DNA samples for bisulfite pyrosequencing were the same as those used for
measurement of global DNA methylation. Sodium bisulfite modification
was performed using the EZ DNA Methylation-Gold kit (Zymo Research)
according to the manufacturer’s instructions. Region 4 for the Kcnq1ot1
CpG island (24) was amplified from 100 ng of bisulfite-treated DNA using
primers mKcnq1ot1 F and mKcnq1ot1 R. The biotinylated bisulfite-mod-
ified PCR products were sequenced using the mKcnq1ot1 sequencing
primer on a PyroMark Q24 pyrosequencer (Qiagen) and analyzed using
the PyroMark Q24 Advanced version 3.0 software. Methylation levels at
each CpG site were measured in triplicate in each tissue.
Homocysteine measurement. Blood from adult / and /Ora
mice was obtained by cardiac puncture. Plasma homocysteine levels were
determined using standard clinical testing parameters (25–28) and a Shi-
madzu LC-20 HPLC and ABSciex 4000 QTrap MS.
Whole mounts, tissue sections, and staining. Embryos were har-
vested at E11.5 and E13.5, fixed, embedded in paraffin, sectioned, and
counterstained with neutral red. Images were acquired with a Leica DFC
420C digital camera attached to either a Leica S8APO or DM2500 micro-
scope, using the Leica Application Suite.
In vitro colony assays. Colony assays were performed in triplicate in
Methocult GF-3434 (Stemcell Technologies). For FL, triplicate dishes
were seeded with 10,000 liver cells. For the aorta-gonad-mesonephros
(AGM) region, the entire AGM was dissociated into single cells and
seeded across 3 dishes. Colonies (burst-forming unit-erythroid [BFU-E],
CFU-granulocyte, macrophage [CFU-GM], and CFU-granulocyte, ery-
throid, macrophage, megakaryocyte [CFU-GEMM]) were scored after 9
to 11 days.
Flow cytometry. For analysis of progenitor cells, mononuclear cells
from/ and/Ora adult BM were isolated by Ficoll separation prior to
staining. For analysis of erythroid maturation, femurs were flushed with
PBS containing 5% bovine serum albumin (BSA) and 2 mM EDTA (flu-
orescence-activated cell sorter [FACS] buffer), and the spleens were
crushed in FACS buffer prior to staining and analysis. For FL analysis, the
entire FL from E13.5 and E11.5 /, /Ora, and Ora/Ora mice was
crushed in FACS buffer prior to staining and analysis. The stained cells
were analyzed using either an LSR Fortessa SORP cell analyzer or a FACS
Canto II analyzer (both BD Biosciences, San Jose, CA).
For analysis of erythroid maturation, cells were first gated as 7-AAD
negative (live) and Ter119 positive, and the resulting population was plot-
ted as CD44 versus forward scatter (FSC). Regions representing six ery-
throid populations (proerythroblasts [I], basophilic erythroblasts [II],
polychromatic erythroblasts [III], orthochromatic erythroblasts [IV], re-
ticulocytes [V], and RBCs [VI]) were drawn essentially as described by Liu
et al. (29).
5-Fluorouracil hematoablation. Age-matched/ and/Ora mice
were injected intraperitoneally with 5-fluorouracil (5FU) (Hospira Aus-
tralia) at 150 mg/kg of body weight. Minimal submandibular blood sam-
ples were taken weekly, diluted in PBS, and analyzed using an Ac · T Diff
analyzer (Beckman Coulter) using equine settings. Undiluted blood was
smeared on slides, dried, and stained with Wright’s stain. Twenty-eight
days following injection, the mice were culled, and the spleens and bone
marrow were collected for flow cytometry analysis of developing ery-
throid populations.
Vascular-function assay. Aortas were harvested from age-matched
/ or /Ora mice (age, 10 to 44 weeks) and placed into prechilled
modified Krebs-Henseleit (KH) buffer (NaCl, 118.4 mmol/liter; KCl, 4.7
mmol/liter; CaCl2, 2.5 mmol/liter; MgSO4, 1.2 mmol/liter; KH2PO4,1.2
mmol/liter; NaHCO3, 25.0 mmol/liter; EDTA, 0.023 mmol/liter; and glu-
cose, 11.1, mmol/liter, pH 7.4). Perivascular adipose and connective tis-
sues were carefully removed from the thoracic aorta, which was cut into
rings 2 mm thick. The aortic rings were then mounted in individual organ
chambers of a Myograph system (MultiMyograph 610M; Danish Myo
Technology, Aarhus, Denmark) containing 6 ml of KH buffer equili-
brated with carbogen gas (95% O2-5% CO2) and maintained at 37°C.
Isometric tension was monitored with a force transducer connected to a
data acquisition system. The tension on each vessel segment was slowly
increased until it reached a resting or baseline tension of 9.8 mN, which
Thoms et al.
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was maintained throughout the remainder of the study. After a 15-min
equilibration period, the segments were stretched to their optimal passive
tension by the response to 125 mM KCl, which induced maximal vessel
contraction. Once the tension reached a plateau, the segments were
washed 4 times with regular KH buffer over 5 min. This KCl contraction/
wash step was repeated twice. After 30 min equilibration, the aortic rings
were placed in KH buffer supplemented with indomethacin (10 mol/
liter to inhibit cyclooxygenase and the synthesis of vasoactive prostan-
oids) and contracted with phenylephrine until a stable contraction pla-
teau of approximately 80% of maximal tension (achieved with 125 mM
KCl) was reached. The concentration-dependent vascular-relaxation re-
sponses induced by the endothelium-dependent dilator acetylcholine
(Ach) (1 nmol/liter to 1 mol/liter) were then recorded. Endothelium-
independent responses were recorded in response to the NO donor
diethylammonium (Z)-1-(N,N-diethylamino)diazen-1-ium-1,2-diolate
(DEANO) (1 nmol/liter to 10mol/liter). Vasorelaxation responses were
expressed as the percent relaxation of the submaximal contraction in re-
sponse to phenylethrine. To examine the effect of sepiapterin supple-
ments on vascular reactivity, aortic rings were incubated with or without
sepiapterin (100 M) for 60 min at 37°C in 1 ml KH buffer in Eppendorf
tubes and subsequently mounted for myography.
RESULTS
Orana mice have a point mutation in Dhfr, the gene encoding
dihydrofolate reductase. We used a recently described method
(18) to carry out a forward recessive genetic screen in mice to
identify genes involved in definitive hematopoiesis. G3 (Fig. 1A)
offspring of ENU-mutagenized males were screened at E14.5 for
altered distributions of hematopoietic populations. Some em-
bryos from pedigree 25 of this screen were small and pale (Fig. 1A;
G3 phenotypically homozygote embryos are indicated by aster-
isks); this line was named Orana (Ora), in line with the naming
convention of the Australian Phenomics Facility, where the line
was generated (18). All three genotypes were present at roughly
Mendelian ratios in E13.5 embryos (26:55:19; n 
 84); however,
homozygosity for the Orana allele was embryonic lethal soon after
E14.5. Flow cytometry analysis of blood from phenotypically mu-
tant embryos indicated a moderate increase in primitive RBCs and
a significant decrease in definitive RBCs (Fig. 1A). There was also
an increase in cKit Sca1 and cKit Sca1 lin (LSK) cells in G3
mice, although this phenotype was not observed following exten-
sive backcrossing onto a C57BL/6J background (all data are ex-
pressed as median percent LSK cells in nucleated FL, range, andn):
E14.5 G3 mice, phenotypically normal (0.74, 0.27 to 1.12, 14) and
phenotypically mutant (2.28, 0.92 to 3.18, 5) (P 	 0.001; t test);
E13.5 backcrossed mice, / (0.475, 0.22 to 3.41, 8), /Ora
(0.535, 0.19 to 1.39), and Ora/Ora (0.55, 0.34 to 0.078, 4). To-
gether, these data suggest that the gene responsible for the Orana
phenotype plays a role in early blood development. After extensive
backcrossing, the Orana mutation was mapped by SNP array and
candidate sequencing to exon 5 of the Dhfr gene on chromosome
13. A single A-to-G mutation was observed at chromosome 13
base 92368224 (mm10) (Fig. 1B), which led to the replacement of
Thr136 with Ala. The crystal structure of DHFR coupled with folic
acid and NADPH indicates that OG1 of Thr136 is hydrogen
bonded to the pteridine moiety of folate through an intervening
FIG 1 Orana mice have a point mutation in Dhfr, the gene encoding dihydrofolate reductase. (A) Schematic showing the ENU mutagenesis and screening
strategy that led to the discovery of the Orana phenotype. The graph shows primitive (prim) RBCs and definitive (def) RBCs in blood from phenotypically normal
(normal) and phenotypically mutant (mutant) E14.5 embryos. *, P	 0.001; t test. The bars in the graphs indicate the medians. (B) Sanger sequencing of/,
/Ora, and Ora/Ora mice showing a single A-G mutation at chromosome 13 base 92368224 (mm10). This mutation leads to an altered amino acid sequence of
the DHFR protein (Thr136Ala). (C) Structure diagram (derived from Protein Data Bank [PDB] 4M6K [32]) showing human DHFR (gray) bound to folate (blue)
and NADPH (not shown), indicating the position of Thr136 (red) in the folded protein. The dotted green lines indicate observed hydrogen bonds between
Thr136, Glu30 (dark gray), water (green circle), and folate (30–32).
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water molecule (Fig. 1C) (30–32). OG1 is absent in Ala, so the
Thr136Ala mutation is predicted to alter the affinity of DHFR for
folic acid and therefore to compromise enzyme function.
The Orana mutation compromises the catalytic activity and
protein stability of DHFR. WT (/), heterozygous (/Ora),
and homozygous (Ora/Ora) E13.5 FLs all expressed DHFR mRNA
at comparable levels, and no difference in expression levels was
observed in adult/ versus/Ora livers (Fig. 2A). However, a
reduction in total DHFR protein was observed in /Ora E13.5
livers, while DHFR was barely detectable in Ora/Ora E13.5 livers
(Fig. 2B). A modest reduction in DHFR levels was observed in
heterozygote adult livers (Fig. 2C), and DHFR activity was also
reduced in/Ora compared to/ adult livers (Fig. 2D). DHFR
protein was essentially undetectable in Ora/Ora embryos and had
reduced expression in /Ora embryos and adults, so we asked
whether the Thr136Ala mutation itself altered DHFR activity. Re-
combinant DHFRWT and DHFROra proteins were readily ex-
pressed in Escherichia coli (Fig. 2E, bottom). While enzyme activ-
ity was detected for recombinant DHFRWT protein, DHFROra was
essentially unable to catalyze the NADPH-dependent conversion
of DHF to THF (Fig. 2E, top). The anti-DHFR antibody detected
low levels of DHFR in the Ora/Ora mice and recognized both WT
(DHFRWT) and Orana (DHFROra) recombinant proteins (Fig. 2E,
bottom), so it is unlikely that the reduced DHFR expression ob-
served in Ora/Ora embryos was due to impaired antibody affinity
for the DHFROra protein. Rather, these data suggest that the mu-
tant DHFROra was synthesized and subsequently degraded, poten-
tially due to misfolding. We tested this hypothesis directly by ex-
pressing DHFRWT and DHFROra in 293T cells (Fig. 2F). At 24 h
after transfection, DHFRWT was readily detectable by Western
blotting. In contrast, no DHFROra could be detected above endog-
enous background. However, treatment of DHFROra-transfected
cells with the proteasomal inhibitor BTZ resulted in increased
DHFR expression and the appearance of partial degradation
products, indicating that the DHFROra protein was degraded via
the proteasome.
Homozygous Orana embryos have defects in folate metabo-
lism consistent with reduced DHFR activity. Having found that
animals harboring the Orana allele had reduced levels of func-
tional DHFR, we next investigated the consequences of this defect
for folate metabolism. The Orana mutation in DHFR is expected
to impair reduction of dietary folic acid into THF and the subse-
quent availability of folate species for methylation reactions (via
5-methyl THF) and DNA synthesis (via 5,10-methylene THF and
5-formyl THF [Fig. 3A]). E13.5 Ora/Ora embryos contained on
average less than half the total tissue folate concentration of/
and /Ora embryos (Fig. 3B). The 5-methyl THF concentration
was 9-fold lower while the folic acid concentration was 15-fold
higher in Ora/Ora embryos compared to/ embryos (Fig. 3B).
This resulted in a substantially perturbed tissue folate distribution
in Ora/Ora embryos compared to / embryos, with a reduced
proportion of 5-methyl THF and an increased proportion of un-
metabolized folic acid, 5,10-methenyl THF, and 5-formyl THF for
DNA synthesis (Fig. 3C). This shift in folate distribution is con-
sistent with the impaired ability of folic acid to be reduced by
DHFR into metabolically active forms. Despite the reduced avail-
ability of 5-methyl THF, a methyl donor required for DNA meth-
ylation, no significant differences in global DNA methylation (Fig.
3D, left), or methylation of a CpG island adjacent to the promoter
of a known imprinted gene, Kcnq1ot1, was detected in Ora/Ora
embryos compared to/ and/Ora embryos (Fig. 3D, right).
In addition to whole embryos, we analyzed the folate concen-
tration and distribution in E13.5 embryonic livers. Similar reduc-
tions in total folate, 5-methyl THF, and THF concentrations were
found in the embryonic livers of Ora/Ora mice compared to/
mice (Fig. 4A). The overall distribution of folate species in the
embryonic liver was also perturbed (Fig. 4B).
Interestingly, no significant differences in the whole embryo or
liver tissue folate concentration or species distribution was found
in/Ora compared to/ samples, which suggested that a single
WT allele ofDhfrwas adequate to sustain folate metabolism of the
embryo in vivo. To determine whether the folate concentration
was also sustained in adult /Ora mice compared to / mice,
we profiled tissue folate species and DNA methylation in six tis-
sues from one adult/mouse and two/Ora mice. We found
that the total folate concentrations in the BM of both/Ora mice
were half that of the/mouse, although folate species distribu-
tions were similar (Fig. 4C). Folate concentrations and distribu-
FIG 2 Mice harboring the Orana (Ora) allele have reduced levels of functional
DHFR. (A) Relative mRNA expression in /, /Ora, and Ora/Ora E13.5
fetal liver and in/ and/Ora adult livers. (B) Protein expression in/,
/Ora, and Ora/Ora E13.5 fetal liver. The numbers indicate DHFR protein
levels normalized to -actin. (C) Relative DHFR protein expression in /
and/Ora adult livers. (D) DHFR activity of equal amounts of protein from
/ and /Ora adult livers. (E) DHFR activity and Western blot of equal
amounts of recombinant WT (DHFRWT) and Orana (DHFROra) DHFR pro-
tein expressed in E. coli. (F) Ectopic expression of WT and Orana DHFR in
293T cells before and after treatment with the proteasomal inhibitor BTZ. The
bars in all the graphs indicate the medians.
Thoms et al.
1226 mcb.asm.org April 2016 Volume 36 Number 8Molecular and Cellular Biology
 o
n
 July 26, 2016 by UQ Library
http://m
cb.asm
.org/
D
ow
nloaded from
 
tions in other tissues, including aorta, liver, small intestine, colon,
and brain, were identical (Fig. 4C and data not shown). Moreover,
global DNA methylation (Fig. 4D and data not shown) and meth-
ylation of a CpG island adjacent to the promoter of a known
imprinted gene, Kcnq1ot1 (Fig. 4E and data not shown), in the
adult / tissues were similar to those in /Ora mice. In some
tissues, we did observe a small increase in average methylation
across the Kcnq1ot1 CpG island (e.g., the liver panel in Fig. 4E);
however, when taken together, our data indicate that decreased
DHFR expression does not lead to substantial changes in either
global methylation or methylation at the imprinted Kcnq1 gene.
We also measured plasma homocysteine levels in adult mice,
since recycling of homocysteine to methionine via methionine
synthase requires a methyl group usually donated by the conver-
sion of 5-methyl THF to THF (33). Consistent with our direct
measurement of folate species and global DNA methylation, we
observed no significant difference in plasma homocysteine con-
centration between/ and/Ora mice (data not shown).
ReducedDHFR function leads to defects in embryonic blood
production. Having originally identified the Orana line based on
its recessive blood phenotype, we further characterized the phe-
notype in Ora/Ora embryos. At E11.5, the gross morphologies
of/,/Ora, and Ora/Ora embryos were similar, although the
livers of Ora/Ora mice appeared slightly paler (Fig. 5A, top). In
contrast, at E13.5, Ora/Ora embryos were smaller and paler than
their / littermates (Fig. 5B, top, and C). The fetal liver is the
FIG 3 Homozygous Orana embryos have defects in folate metabolism consistent with reduced DHFR activity. (A) Simplified flow chart of folate-mediated
one-carbon metabolism illustrating the roles of different folate species. Dietary folic acid is reduced by the enzyme DHFR to DHF and THF. THF is converted to
5,10-methylene THF, an essential precursor for thymidylate synthesis, which is the rate-limiting step in DNA synthesis. 5,10-Methenyl THF and 5-formyl THF
play important roles in purine synthesis. The recycling of 1 carbons back to THF occurs via 5-methyl THF, which is a critical folate species for methylation
reactions, particularly DNA methylation. The consequences of a deficiency or imbalance of folate species are summarized. (B) Concentrations of folate species
in / (n 
 3), /Ora (n 
 6), and Ora/Ora (n 
 2) E13.5 whole embryos. P values are indicated (one-way analysis of variance [ANOVA]). (C) Overall
abundance and distribution of folate species in E13.5 whole embryos. (D) DNA methylation levels in E13.5 whole embryos. (Left) Global. (Right) At individual
CpGs adjacent to theKcnq1ot1 promoter. The horizontal lines indicate mean methylation levels across all 10 CpGs for/ (black line; mean
 24.76%),/Ora
(red line; mean
 25.92%), and Ora/Ora (blue line; mean
 27.75%). The bars in all the plots indicate the medians.
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primary hematopoietic organ at E11.5, having been seeded by
HSCs formed in the AGM (34–36). Close inspection of the E11.5
liver revealed a reduction in erythrocytes in Ora/Ora mice (Fig.
5A, bottom), indicating that reduced DHFR led to reduced blood
production. A reduction in erythrocytes was also observed in
E13.5 livers (Fig. 5B, bottom). This is consistent with the reduc-
tion in definitive RBCs observed during the initial ENU mutagen-
esis screen (Fig. 1A). We next assessed whether blood progenitors
from the FL and AGM were functional using colony assays. At
E11.5, there was a significant decrease in BFU-E, CFU-GM, and
CFU-GEMM colonies in Ora/Ora embryos (Fig. 6A), which indi-
cated a reduced number of functional progenitor cells in the rap-
idly expanding hematopoietic FL compartment. In contrast, pro-
genitor cells in the AGM of Ora/Ora embryos were able to generate
BFU-E and CFU-GM colonies, although the numbers of the more
primitive CFU-GEMM colonies were reduced (Fig. 6B). BFU-E and
FIG 4 Homozygous Orana FLs have defects in folate metabolism consistent with reduced DHFR activity, while adult heterozygotes have altered folate
metabolism in a subset of tissues. (A) Concentrations of folate species in/ (n
 3),/Ora (n
 6), and Ora/Ora (n
 2) E13.5 livers. The bars in the
graphs indicate the medians. (B) Overall abundance and distribution of folate species in E13.5 livers. (C) Overall abundance and distribution of folate
species in adult aorta, bone marrow, and liver, *, pregnant/Ora mouse. (D) Global DNA methylation level in adult aorta, bone marrow, and liver. (E)
Methylation of individual CpGs adjacent to the Kcnq1 promoter in adult aorta, bone marrow, and liver. The horizontal lines indicate mean methylation
across all 10 CpGs for / (black line; aorta mean 
 27.43%, BM mean 
 23.6%, and liver mean 
 20.52%), /Ora (red line; aorta mean 
 26.11%,
BM mean 
 24.26%, and liver mean 
 24.00%), and pregnant /Ora (dashed red line; aorta mean 
 24.97%, BM mean 
 25.63%, and liver mean 

24.02%). The error bars indicate standard errors of the means (SEM).
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FIG 5 Reduced DHFR function leads to altered embryonic morphology and reduced erythrocyte production in the fetal liver. (A) Whole mounts of /,
/Ora, and Ora/Ora E11.5 embryos and corresponding neutral-red-stained fetal liver sections. (B) Whole mounts of/,/Ora, and Ora/Ora E13.5 embryos
and corresponding neutral-red-stained fetal liver sections. (C) Crown-to-rump measurements of E11.5 and E13.5 embryos. *, P	 0.05 (t test). The bars in the
graph indicate the medians.
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CFU-GEMM colonies were also reduced in E13.5 Ora/Ora livers (Fig.
6C). These data suggest an early functional defect in both the ery-
throid and the most immature progenitor compartments. We also
directly measured progenitor cells in E13.5 FLs and found that, while
the number of functional progenitors was reduced, the percentage of
cKit and LSK cells in Ora/Ora livers was the same as in/ livers
(Fig. 6D). Additionally, at both E11.5 and E13.5, the FLs of Ora/Ora
embryos contained fewer cells than / embryos (Fig. 6E). To-
gether, these data indicate that definitive hematopoiesis is initiated in
Ora/Ora mice and that blood progenitors successfully migrate to and
colonize the FL, but they have a reduced capacity to undergo subse-
quent differentiation and expansion to form terminal blood types,
particularly within the erythroid lineage.
Reduced DHFR leads to alterations in the erythroid com-
partment of resting and 5-fluorouracil-treated/Oramice. We
then asked whether the small reduction in DHFR observed in/
Ora mice leads to phenotypic differences in adult mice. We first
compared the numbers of a range of progenitor cells in the bone
marrow of adult/ and/Ora mice. Flow cytometric analysis
indicated that MEPs, but not GMPs or CMPs, were reduced in/
Ora mice (Fig. 7A). Given this phenotype, the reduction in overall
folate species in BM (Fig. 4C), our observations that BFU-E were
FIG 6 Reduced DHFR function leads to defects in embryonic blood production. (A and B) Functional assays of blood progenitors in E11.5 FL (A) and
AGM (B). P values are indicated (one-way ANOVA). (C) Functional assays of blood progenitors in E13.5 FLs. P values are indicated (one-way ANOVA).
(D) Flow cytometry analysis of cKit and LSK cells in E13.5 FLs. (E) Total cells per FL at E11.5 and E13.5. P values are indicated (one-way ANOVA). The
bars in the graphs indicate the medians.
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FIG 7 Reduced DHFR function leads to alterations in the erythroid compartment and impaired response to 5FU-induced hematoablation. (A) Flow cytometry
analysis of blood progenitors in adult bone marrow. *, P	 0.05 (t test). The bars in all the graphs indicate the medians; each data point indicates an individual
mouse. (B) Representative flow cytometry plot indicating gates used to determine maturing erythroid populations in panels B and F. The graphs show relative
abundances of Ter119 erythroid populations in BM and spleens of/ and/Ora adult mice. *, P	 0.05 (t test). (C) Peripheral blood RBC counts in young
and older/ and/Ora mice. (D) Plots showing total TNC, Hgb, and platelets in peripheral blood (PB) of 8- to 9-month-old/ and/Ora mice following
5FU treatment. *, P	 0.05 (t test). (E) Spleens of 8- to 9-month-old/ and/Ora mice 28 days after 5FU treatment. The asterisk indicates the spleen from
mouse 503. (F) Relative abundances of Ter119 erythroid populations in BM and spleens of 8- to 9-month-old/ and/Ora adult mice 28 days after 5FU
treatment. *, P 	 0.05 (t test). The data points from the spleen of mouse 503 (red squares marked with ) were excluded from statistical analysis. (G) Plots
showing TNC of 2- to 3-month-old/ and/Ora mice following 5FU treatment. (H) Wright-stained PB smears from 2- to 3-month-old/ and/Ora
mice following 5FU treatment. The arrows indicate abundant nucleated red cells in the peripheral blood. The error bars indicate SEM.
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reduced in Ora/Ora FLs at E11.5 and E13.5 (Fig. 6A and C), and
the known requirement for folate in erythropoiesis (37), we asked
whether erythroid maturation was altered in /Ora mice. In the
BM, there was a trend toward reduced proportions of nucleated
erythroblasts (Fig. 7B, left graph, II to IV) and a significant in-
crease in the proportion of mature erythrocytes (Fig. 7B, VI), sug-
gesting that erythrocyte release is delayed in /Ora mice. The
gross spleen morphology was unchanged between / and
/Ora mice (data not shown), but flow cytometry analysis of
erythroid maturation showed a trend toward increased propor-
tions of nucleated erythroblasts (Fig. 7B, right graph, I to IV).
However, these changes did not translate to alterations in the
number of circulating RBCs at any age (Fig. 7C).
We next asked whether we could reveal a more striking pheno-
type in/Ora mice under conditions of stress hematopoiesis. We
treated a cohort of older (8- to 9-month-old) / and /Ora
mice with 5FU, which kills cycling hematopoietic cells but spares
the quiescent HSCs, which are then stimulated into the cell cycle
to repopulate the depleted marrow. As expected, total nucleated
cells (TNC), hemoglobin (Hgb), and platelets dropped in the first
7 days after treatment and then recovered over the following 3
weeks (Fig. 7D). We observed a striking increase in TNC at day 14
in/Ora mice compared to/ controls, which resolved by day
21 (Fig. 7D). At day 28, /Ora mice had marked splenomegaly
(Fig. 7E), highlighting the fact that /Ora mice have prolonged
extramedullary hematopoiesis. This splenomegaly was not ob-
served in untreated mice of similar age (data not shown). Day 28
BM looked similar to the untreated controls (compare Fig. 7F to
B). Despite the splenomegaly observed in the 5FU-treated/Ora
mice, the distributions of maturing erythroid cells in the spleen
were similar between/ and/Ora mice, with the exception of
erythrocytes (Fig. 7F, VI) which were present in slightly higher
numbers in the/Ora mice.
We hypothesized that the increased nucleated cells observed in
peripheral blood at day 14 were not leukocytes but rather nucleated
red cells that appeared in the circulation in response to hematopoietic
stress. To test this hypothesis, we treated an additional cohort of
younger (2- to 3-month-old)/ and/Ora mice with 5FU. We
once again observed an increase in TNC at day 14 (Fig. 7G). Periph-
eral blood smears indicated a marked increase in nucleated red blood
cells in/Ora mice at day 14, consistent with the notion that/Ora
mice release immature nucleated red cells into the circulation under
stress hematopoiesis conditions. Together, these data indicate that
although/Ora mice show mild changes in erythroid maturation at
rest, these mice are able to produce normal numbers of circulating
erythrocytes. However, following treatment with 5FU, /Ora
mice have perturbed erythropoiesis consistent with prolonged
extramedullary hematopoiesis.
Reduced DHFR leads to impaired endothelium-dependent
vasorelaxation inOranamice, which can be restored by bolster-
ing BH4 levels with sepiapterin. Along with its primary role in
converting dietary folate to THF, DHFR has a secondary role in
BH4 recycling, where it reduces BH2 to BH4 to maintain the ho-
meostatic cellular BH4/BH2 ratio. This in turn prevents eNOS
uncoupling and maintains NO bioactivity and endothelial func-
tion (Fig. 8A) (4, 38, 39). To examine the effect of DHFR deficiency
on endothelial function in Orana mice, endothelium-dependent re-
laxation responses were measured in aortic rings from adult/and
/Ora mice. Endothelium-dependent relaxation was significantly
impaired in aortas from /Ora mice compared to / mice
(Fig. 8B). No significant difference was observed for endothelium-
independent aortic relaxation induced by the NO donor DEANO
(Fig. 8C and E), indicating that the relaxation defect observed in
/Ora mice was a result of altered endothelium-derived NO signal-
ing and not an intrinsic defect in the aorta itself. Elevating vascular
BH4 levels by preincubating vessels with sepiapterin restored endo-
thelium-dependent relaxation responses in /Ora mouse aortic
rings to those seen in/mice (Fig. 8D). These data verify that the
endothelium in /Ora aortas was dysfunctional, providing further
FIG 8 Reduced DHFR leads to impaired endothelium-dependent vasorelax-
ation in Orana mice, which can be restored by bolstering BH4 levels with
sepiapterin. (A) Schematic representation of de novo BH4 synthesis and recy-
cling pathways. BH4 is synthesized de novo from GTP via a series of reactions
involving the rate-limiting enzyme GTPCH-1 and sepiapterin reductase (SR).
BH4 is oxidized to BH2 in cells. DHFR can regenerate BH4 from BH2 via the
recycling pathway. eNOS coupling is maintained when it is bound to BH4,
producing NO, whereas BH2-bound eNOS leads to uncoupling and subse-
quent production of superoxide instead of NO. (B and C) Endothelium-de-
pendent relaxation responses to Ach (B) and endothelium-independent relax-
ation responses to DEANO (C) of/ or/Ora mice. The data are means
SEM (n 
 5). *, significant (P 	 0.05) difference between / and /Ora
aortic rings (unpaired t test). (D and E) Endothelium-dependent vasorelax-
ation responses to Ach (D) and endothelium-independent relaxation re-
sponses to DEANO (E) of/ or/Ora mice in the absence or presence of
sepiapterin (Sepi) (100 mol/liter; 1 h preincubation). The data are means
SEM (n
 3). *, significant (P	 0.05) difference between/Ora and/Ora
Sepi aortic rings (unpaired t test). The relaxation responses to Ach or DEANO
were recorded after vessel contraction with phenylephrine (300 nmol/liter).
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support for the previously described role of DHFR in maintaining
endothelial BH4 levels through reduction of BH2 (38) and thereby
preserving endothelium-dependent vasorelaxation responses.
DISCUSSION
In this study, we describe a mouse generated through an ENU
mutagenesis screen that has a single point mutation in the Dhfr
locus leading to a Thr136Ala substitution in the DHFR protein.
Homozygote animals died of blood defects between E13.5 and
E14.5, while heterozygote adults survived with a relatively intact
blood compartment but showed tissue-specific defects in distri-
bution of folate species and impaired vascular endothelial func-
tion. The Thr136Ala substitution is predicted to result in reduced
affinity of DHFR for its substrate, consistent with our observation
that the enzyme activity of recombinant DHFROra was blunted.
Interestingly, in vitro mutagenesis of Glu30, an amino acid that
also forms a hydrogen bond with the pteridine moiety of folate
(30, 32) and bonds directly to Thr136 (31, 32), produced a cata-
lytically inactive form of DHFR (40). The Thr136Ala mutated
version of the DHFR protein (DHFROra) was barely detectable in
either Ora/Ora mice or 293T cells transfected with a DHFR cDNA
encoding the mutated version. Full-length and truncated versions
of DHFROra could be detected in transfected 293T cells treated
with the proteasome inhibitor bortezomib, suggesting that
DHFROra was produced in cells but rapidly degraded.
Several families with mutations in the coding region of DHFR
have been described in the literature. Individuals with deficiencies
in DHFR are anemic and show various neurological symptoms
(15, 16). Banka and colleagues (15) have described two apparently
unrelated families in which infants presented with megaloblastic
anemia and seizures. Subsequent genetic analysis in both families
revealed a Leu80Phe substitution in DHFR, which is predicted to
disrupt binding of the essential cofactor NADPH. However, West-
ern blot analysis of an affected individual compared to controls
and a heterozygote parent indicated that the DHFR protein was
essentially absent in the homozygote. The lack of DHFR in these
patients is similar to our findings with the Orana mouse, although
the absence of DHFR appears to have less severe consequences in
humans, since Ora/Ora mice die by E14.5. In contrast, affected
humans survived into early childhood in cases where the DHFR
deficiency was recognized and treated with folinic acid supple-
ments. We attempted to rescue Ora/Ora pups with maternal fo-
linic acid supplementation, but this did not yield an Ora/Ora ne-
onate (data not shown). Interestingly, the proband in the first
family was also identified as having low levels of BH4, but normal
BH2, in the cerebrospinal fluid (CSF). This would be predicted to
have effects on eNOS similar to those we describe here in/Ora
mice. A second family with an Asp153Val substitution has also
been described (16). This mutation appears to be less disruptive to
normal DHFR function than either Leu80Phe or Thr136Ala
(Orana). DHFR protein was detectable at variable levels in all
three affected patients; two patients with substantially lower
DHFR both presented with childhood absence epilepsy and meg-
aloblastic changes in the bone marrow.
A common feature in the human DHFR cases and our Orana
mouse is defective blood production, as indicated by anemia in the
human cases and reduced functional blood progenitors in Ora/
Ora mice. Together, these data present a strong case for implicat-
ing DHFR as playing a role in definitive hematopoiesis. Our
analysis of Ora/Ora embryos indicates a critical defect in he-
matopoietic progenitor expansion in the fetal liver. HSCs are
initially formed in the AGM and then migrate to the FL, which
is the primary embryonic hematopoietic organ from about
E11.5 (34–36). Functional progenitor cells were present in the
AGM at E11.5, and flow cytometry analysis indicated that the
progenitor cells migrated normally and were present in the FL
at E13.5, despite having reduced capacity to expand. Thus, the
DHFR-induced defect is not in blood formation per se but
rather reflects an inability to expand progenitors and form the
terminal blood cell types. We have not quantified whether the
absolute numbers of HSCs generated by Ora/Ora mice are al-
tered compared to / mice; however, data from human pa-
tients with absent DHFR protein (identified in the postnatal
period) combined with the data presented here suggest that the
reduced DHFR primarily affects progenitor cell expansion
rather than generation of HSCs per se. Further experimentation
would be required to resolve whether the changes observed in
FLs are cell autonomous or are a result of DHFR-dependent
alterations in the surrounding microenvironment, as well as
the progenitor cells themselves.
Our observations regarding embryonic blood production are
consistent with the key role that DHFR plays in DNA synthesis and
maintenance of DNA methylation, both of which are rate-limiting
processes in cell proliferation. Although/Ora mice have marginally
reduced DHFR protein, hematopoietic progenitor expansion was
similar to that in controls, while the adult mice had normal blood
counts and only very mild changes in erythroid maturation at steady
state. However, erythropoiesis was significantly perturbed under
stress conditions in the /Ora mice, with nucleated erythroblasts
observed in the peripheral blood at day 14 following treatment with
5FU. It is unclear why the rapid proliferation of early embryogenesis
is not impaired in Ora/Ora mice. Presumably, maternal folate stores
are sufficient to maintain DNA synthesis and methylation through
the early stages of embryogenesis but are inadequate to support ex-
tensive proliferation of blood progenitors by E13.5. This study also
links DHFR deficiency to defective NO regulation in the vasculature.
It is known that NO mediates HSC emergence from the AGM and
perturbation of NO reduces hematopoietic potential in vitro and in
vivo (41, 42). It is possible that the reduced progenitor expansion we
observed in Ora/Ora embryos is due not only to compromised folate
metabolism but also to effects of reduced DHFR on NO signaling in
the AGM and the emergence of HSCs.
DHFR is critical for converting dietary folate into THF, and its
downstream folate species are required for both DNA synthesis and
methylation reactions. As expected, the distribution of folate species
in Ora/Ora embryos was substantially altered, with a clear increase in
the concentration of folic acid and a concomitant decrease in THF.
Surprisingly, we did not observe differences in global DNA methyl-
ation in Ora/Ora embryos or differences in methylation within the
CpG island of a known imprinted gene, which suggested that mater-
nally derived folate was sufficient to maintain methyl donors (at least
to E13.5). Even though we saw no changes in global DNA methyl-
ation, or methylation at the imprinted gene Kcnq1ot1, in either Ora/
Ora embryos or/Ora adults, we cannot rule out the possibility that
the DHFR deficiency in Orana mice led to epigenetic changes at loci
other than the one measured here. Previous studies have shown that
there is no change in DNA methylation in either the erythroblasts of
folate-deficient mice (37) or the BM of human patients with vitamin
B12 deficiency anemia (vitamin B12 is required for conversion of
5-methyl THF to THF) (43).
Our investigations uncovered a number of hematopoietic
changes in Ora/Ora and/Ora mice compared to/ controls.
These changes were largely centered on the erythroid compart-
ment, which is consistent with the known requirements for folate
in erythroid development (37). In/Ora adults, erythroid matu-
ration in both the BM and spleen was altered compared to /
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mice. Specifically, we saw an overall reduction in nucleated eryth-
roblasts in the BM and a concomitant increase in nucleated eryth-
roblasts in the spleen. This phenotype is mild but suggests that the
erythroid compartment is sensitive to even the small reduction in
DHFR protein and subsequent reduction in folate concentration
in the BM of /Ora mice. These mice are able to compensate
under steady-state conditions, possibly by increasing erythroid
maturation in the spleen. A more striking phenotype became ap-
parent in the/Ora animals following treatment with 5FU, where
we saw a large efflux of nucleated red cells into the circulation on
day 14. Treatment with 5FU is known to damage the BM vascula-
ture (44) and is likely to also damage the vasculature in other
organs, including the spleen. Assuming that the /Ora spleen
continues to produce more nucleated red cells than/ controls
following 5FU treatment (as observed at steady state), the in-
creased nucleated red cells in the circulation of 5FU-treated
/Ora mice may be due to a combination of increased output
from the spleen (and BM) and damaged vasculature with de-
creased capacity to regulate erythroblast release. Given that the
/Ora mice also have altered NO regulation in the vasculature
(Fig. 8), it is likely that the combination of increased erythroblast
production in the spleen, vascular damage, and altered endothelium-
dependent vasorelaxation collectively produces the increased circu-
lating nucleated erythroblasts. Alternatively, day 14 after 5FU treat-
ment is the peak period of HSC mobilization, and this process may
also involve release of erythroid cells into the circulation. Taking the
data together, it is clear that while/Ora mice can compensate for
erythroid defects at steady state, their ability to increase hematopoie-
sis under stress conditions is compromised.
A feature of vascular diseases, such as diabetes, hypertension,
and atherosclerosis, is endothelial dysfunction that manifests as a
reduction in the bioactivity of NO produced by the endothelium.
Considerable evidence has identified oxidative stress as an impor-
tant cause of such endothelial dysfunction (6). More specifically,
the endothelium from diseased vessels produces increased levels
of O2˙
 that rapidly reacts with NO to form peroxynitrite, a reac-
tion that impairs NO bioactivity (6). It is apparent that during
disease, eNOS itself acts as a significant source of O2˙
 when its
electron flow is “uncoupled” and O2 accepts a terminal electron,
generating O2˙
 instead of NO. A key determinant of eNOS cou-
pling is the maintenance of a homeostatic BH4/BH2 ratio that is
governed by the biosynthesis of BH4 by GTP-cylohydrolase-1
(GTPCH-1) and recycling of BH2 back to BH4 by DHFR (38).
Thus, small interfering RNA (siRNA) inhibition of DHFR expres-
sion in endothelial cells elevates BH2 levels relative to BH4, with
the increased BH2 capable of displacing eNOS-bound BH4, pro-
ducing uncoupled eNOS, elevated O2˙
, and impaired NO bioac-
tivity (4, 38, 39). Employing the novel Orana mouse, our data
provide in vivo support for a key role for DHFR in the mainte-
nance of endothelial BH4 levels, NO bioactivity, and endothelial
function within intact mouse blood vessels. Thus, adult /Ora
mice exhibited impaired endothelium-dependent vasorelaxation
in a manner that was reversed by bolstering BH4 levels via the ex
vivo supplementation of aortas with the BH4 precursor sepiap-
terin. The finding that sepiapterin supplements effectively re-
stored endothelial function in/Ora mice suggests that although
the in vivo deficiency in DHFR in Orana heterozygotes impairs
NO bioactivity and endothelium-dependent relaxation, sufficient
wild-type DHFR enzyme is available to convert excess ex vivo se-
piapterin supplements into BH4 via the salvage pathway. These
data are consistent with DHFR deficiency in /Ora adult mice,
resulting in an imbalance in the BH4/BH2 ratio, eNOS uncou-
pling, and impaired bioactivity of endothelium-derived NO.
The current study indicates that in vivo DHFR gene deficiency
alone in mice impairs endothelial function in the absence of any car-
diovascular disease or metabolic stress. DHFR expression levels are
reduced in the aortas of diabetic mice (45, 46), angiotensin II-infused
wild-type mice (47), BH4-deficient hph-1 mice, (48), ApoE gene
knockout mice (49), and aged hypercholesterolemic LDL receptor
gene knockout mice (50), which all correlates with reduced vascular
BH4 levels and NO bioactivity. Where examined, restoration of
DHFR levels via endothelium-targeted overexpression of the DHFR
gene or folic acid supplements prevents eNOS uncoupling and inhib-
its the degree of hypertension or aortic aneurysm in Ang II-infused
hph-1 (48) or ApoE gene knockout (49) mice and improves endo-
thelial function in diabetic mice (46). Accordingly, the Orana hetero-
zygote mouse represents a promising model to further define the in
vivo role of DHFR in cardiovascular disease, similar to the hph-1
mouse also generated by ENU mutagenesis as a model of BH4 defi-
ciency due to 90% constitutive reduction in GTPCH-1 activity (51).
The hph-1 mouse has been instrumental in establishing the impor-
tance of GTPCH and BH4 in cardiac autonomic regulation (52) and
protection against pulmonary hypertension (53, 54), in vivo eNOS
uncoupling (55), and endothelial progenitor cell number and func-
tion during hypertension (56).
Orana mice should serve as a useful model for probing the
in vivo function of DHFR, particularly its role in regulating NO
signaling and its impact on hematopoietic stem cell emergence,
erythroid maturation, and cardiovascular homeostasis. They will
also be a useful tool to probe tissue- and locus-specific aberrations
in DNA methylation and cancer susceptibility due to sustained
defects in folate metabolism.
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